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Accepted 24 November 2019; Published online 28 November 2019AbstractObjectives: To examine key methodological considerations for using a placebo intervention in randomized controlled trials (RCTs)
evaluating invasive procedures, including surgery.
Study Design and Setting: RCTs comparing an invasive procedure with a placebo were included in this systematic review. Articles
published from database inception to December 31, 2017, were retrieved from Ovid MEDLINE, Ovid EMBASE and CENTRAL electronic
databases, by handsearching references and expert knowledge. Data on trial characteristics (clinical area, nature of invasive procedure,
number of patients and centers) and key methodological (rationale for using placebos, minimization of risk, information provision, offering
the treatment intervention to patients randomized to placebo, delivery of cointerventions, and intervention standardization and fidelity) were
extracted and summarized descriptively.
Results: One hundred thirteen articles reporting 96 RCTs were identified. Most were conducted in gastrointestinal surgery (n 5 40,
42%) and evaluated minimally invasive procedures (n 5 44, 46%). Over two-thirds randomized fewer than 100 patients (n 5 65, 68%)
and a third were single center (n 5 31, 32%). A third (n 5 33, 34%) did not report a rationale for using a placebo. Most common strategies
to minimize patient risk were operator skill (n 5 22, 23%) and independent data monitoring (n 5 28, 29%). Provision of patient informa-
tion regarding placebo use was infrequently reported (n 5 11, 11%). Treatment interventions were offered to patients randomized to pla-
cebo in 43 trials (45%). Cointerventions were inconsistently reported, but 64 trials (67%) stated that anesthesia was matched between
groups. Attempts to standardize interventions and monitor their delivery were reported in n 5 7, (7%) and n 5 4, (4%) trials, respectively.
Conclusion: Most placebo-controlled trials in surgery evaluate minor surgical procedures and currently there is inconsistent reporting
of key trial methods. There is a need for guidance to optimize the transparency of trial reporting in this area.  2019 The Authors. Pub-
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Key findings
 Ninety-six placebo-controlled randomised trials of
invasive procedures published up to December
2017 were identified. Most were conducted in
gastrointestinal surgery (n 5 40, 42%) and evalu-
ated minimally invasive procedures (n 5 44, 46%).
 There was limited and inconsistent reporting of in-
formation regarding the rationale for the study, in-
formation provision to patients, methods used to
minimise risk and standardisation and monitoring
of intervention delivery.
What this study adds to what was known?
 This review comprehensively identified all publica-
tions of placebo-controlled trials of invasive pro-
cedures and examined key methodological issues
that have not been explored in previous reviews.
What is the implication and what should change?
 Findings highlight the need for reporting guide-
lines reflecting methodological best practice for
the design and delivery of placebo-controlled
studies of invasive procedures. This would include
the minimum detail that researchers should state in
trial protocols and in the reporting of results to
ensure transparency and consistency across studies.
1. Introduction
Worldwide, there are at least 230 million invasive pro-
cedures performed annually [1]. Historically, the effective-
ness of these procedures was rarely assessed through high-
quality evidence from randomized controlled trials (RCTs).
However, recent initiatives led by the Royal College of Sur-
geons of England [2], and investment by international fund-
ing bodies [3e5], has facilitated an increase in the number
and quality of RCTs in surgery [6]. Despite these improve-
ments, a remaining challenge relates to the design and de-
livery of placebo-controlled RCTs involving invasive
procedures.
Placebo-controlled trials are considered the gold standard
in the evaluation of health-care interventions because they
optimize blinding of all stakeholders and thereby minimize
bias. Placebo-controlled trials in surgery have been summa-
rized in reviews focusing on treatment effectiveness [7e9],
adverse events [7,8], challenges with recruitment and reten-
tion [10,11], the natural history of placebo responses
[12,13], and the characteristics of the treatment interventions
evaluated [9,10]. Collectively, these have established that
they are feasible, although recruitment can be difficult, and
that most trials evaluated less invasive minimal accesstreatments with few including a traditional ‘‘open’’/‘‘large
cut’’ surgical procedures (i.e., most performed in endoscopic
settings and without the use of general anesthesia).
Although these reviews are useful, several methodolog-
ical features are unexplored. Reported rationales for the use
of an invasive placebo intervention (rather than ‘‘standard
care’’ or other treatment interventions) were not examined.
This is important because of the potential risk associated
with the delivery of invasive placebo interventions (and/or
associated anesthesia). Furthermore, reviews did not
examine how potential risks might be minimized and how
patients are informed about placebo interventions,
including whether enhanced consent processes and extra
safeguards are used, as suggested by guidelines [14e17].
The extent to which patients randomized to placebo groups
are offered treatment interventions is also unknown and is
important because it presents an additional degree of risk
to patients and may influence recruitment. Finally, the re-
views did not examine how to optimize placebo interven-
tion design by consideration of the complexity of the
treatment interventions and the additional diagnostic or
therapeutic procedures delivered to patients as part of the
treatment program (cointerventions) [18]. Specifically, the
extent to which cointerventions are delivered in the placebo
group and methods to standardize interventions and
monitor fidelity to the protocol during the study were not
studied.
The aim of this work was to conduct a systematic review
to examine the reporting of these important methodological
issues in placebo-controlled trials of invasive procedures.2. Methods
A systematic review of RCTs comparing an invasive pro-
cedure with a placebo intervention was undertaken. Articles
identified in a previous review [10] published between data-
base inception and November 14, 2014, were included
(n 5 63). Searches using the same search terms [7]
(Appendix 1) and electronic databases (Ovid MEDLINE,
Ovid EMBASE, and CENTRAL [19]) were conducted to
identify RCTs published from November 15, 2017, to
December 31, 2017. Additional articles, with no restriction
on publication date, were identified by hand searching refer-
ences of included articles and expert knowledge.2.1. Eligibility criteria
Articles reporting RCTs (including long-term follow-ups
and protocols) comparing an invasive procedure with a pla-
cebo procedure in living humans were included. Pilot RCTs
retrieved by the current search were included as a source of
potentially useful information about the main trial methods.
An invasive procedure was defined as any interventional
procedure that changes the anatomy and requires a skin
incision or the use of endoscopic techniques. The term
111S. Cousins et al. / Journal of Clinical Epidemiology 119 (2020) 109e116‘‘placebo’’ referred to a surgical placebo, a sham surgery, or
a procedure intended to mimic the active intervention.
RCTs that assessed medicinal products or dental interven-
tions, nonrandomized studies, reviews, editorials, letters,
and conference abstracts were excluded.2.2. Screening articles
All articles retrieved from the current search (November
15, 2017eDecember 31, 2017) were imported into an
EndNote database (EndNote, version X8.0.2). Titles
and abstracts were screened for eligibility, and full texts
of potentially eligible articles were retrieved, and eligibility
was confirmed. Screening was conducted independently by
two reviewers (S.C. and K.C.).2.3. Data extraction
Data were extracted from all articles, including study
protocols and clinical trial registry reports, where available,
by one reviewer using a standardized data extraction form.
A second reviewer extracted data for 20% of articles to
identify any potential systematic errors in data extraction;
however, none were found. Where multiple articles related
to the same trial included, they were grouped into a single
set, and data extraction was then conducted on a ‘‘per trial’’
(rather than ‘‘per article’’) basis.
Data were extracted on trial characteristics and key meth-
odological areas of interest. Trial characteristics included
year of publication, clinical area (e.g., gastrointestinal),
number of study sites and patients randomized, and type
of treatment intervention (e.g., endoscopic). Key methodo-
logical areas of interest included (i) rationale for use of an
invasive placebo intervention; (ii) minimization of risk;
(iii) information provision and informed consent; (iv) offer-
ing the treatment intervention to patients randomized to the
placebo group; (v) delivery of cointerventions in the placebo
group; and (vi) intervention standardization and fidelity.2.3.1. Rationale for use of an invasive placebo
intervention
Reported rationales for using an invasive placebo inter-
vention were extracted from the introduction section of ar-
ticles. This included, but was not limited to, any report of
its use to measure the placebo effect, reduce bias, or to
determine the mechanism of action of the treatment
intervention.2.3.2. Minimization of risk
Some information on processes to mitigate potential pa-
tient risk was extracted. This included details about technical
skill (e.g., trial entry criteria such as having performed a
minimum number of procedures), use of trial oversight or
monitoring mechanisms (e.g., independent committees), or
the use of explicit emergency unblinding protocols.2.3.3. Information provision and informed consent
Information provided to patients during informed con-
sent regarding the use of a placebo intervention was
extracted.
2.3.4. Offering the treatment intervention to patients
randomized to the placebo group
Whether the treatment intervention was offered to pa-
tients randomized to the placebo group at any point was ex-
tracted, including whether a rationale for this was reported.
2.3.5. Delivery of co-interventions in the placebo group
It was reported whether the delivery of cointerventions
(before, during, or after the invasive procedure) was
matched between treatment and placebo groups. Specif-
ically, whether anesthesia (not including premedications)
was matched between groups, and if so, the type of anes-
thesia (local, general, or sedation) used was extracted.
2.3.6. Intervention standardization and fidelity
Strategies to standardize treatment and placebo interven-
tions and to monitor their delivery (e.g., videotaping) were
captured.3. Results
Current searches retrieved 1,854 articles, of which 75
full texts were screened and 50 were included (Fig. 1).
Combined with 63 articles from the previous review [10],
a total of 113 articles relating to 96 unique trials formed
the final data set (Table 1). Most were conducted in gastro-
intestinal surgery (n 5 40, 42%) and evaluated minimally
invasive or endoscopic interventions (n 5 44, 46%). Over
two-thirds randomized fewer than 100 patients (n 5 65,
68%) and approximately one-third involved a single center
(n 5 31, 32%).
3.1. Rationale for the use of an invasive placebo
intervention
Thirty-three trials (34%) did not report any rationale for
using a placebo intervention. Approximately one-third
(n 5 27, 28%) justified the use of a placebo in terms of
quantifying potential placebo effects. This included discus-
sion of the limitations of previous noneplacebo-controlled
trials and known or expected placebo effects associated
either with interventions of the same nature (invasive) or
with the specific treatment intervention under evaluation
[20e22]. The role of placebo interventions in reducing bias
within RCTs was mentioned in nine trials (9%). These tri-
als critiqued previous ‘‘open-label’’ studies evaluating the
treatment intervention [20,23e26] and highlighted the
methodological advantages of using placebo interventions
owing to their ability to control for bias [27e29]. Using a
placebo intervention to help elucidate a treatment’s
Fig. 1. PRISMA diagram showing screening process of retrieved articles.
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rationale for use of a placebo. However, 10 trials (10%)
implied this by stating an uncertainty over which treatment
components were responsible for the mechanism of action.3.2. Minimization of risk
Information about degree of operator skill was reported
in 22 (23%) trials. Independent data monitoring was re-
ported in 28 trials (29%). Of these, 17 explicitly reported
monitoring of safety outcomes and 12 reported the use of
formal interim analyses. Another trial [30] explicitly re-
ported the use of a prospectively designed protocol under
which patients would be unblinded to treatment received
in the case of medical emergency.3.3. Information provision and informed consent
Eleven trials (11%) reported details of information given
to patients related to the use of a placebo intervention. Tworequired patients to write statements stating that they real-
ized that they may receive placebo surgery and they further
realized that this placebo surgery would not benefit their
condition [31,32]. Similarly, one trial stated that patients
were made to realize that they may receive only placebo
surgery in which case their condition would be left un-
treated [33]. In contrast, one informed patients that the pla-
cebo procedure might improve symptoms [34]. Three trials
[20,28,35] did not use the term ‘‘placebo’’ or ‘‘sham’’ in in-
formation given to patients, but rather they described the
characteristics of both treatment and placebo procedures.
Only two trials reported that patients were informed that
they might not receive the treatment intervention [26,36],
and one informed patients of the ‘‘blinded’’ nature of the
study [37].
Only one trial [38] defined placebo surgery in informa-
tion provided to patients (‘‘placebo surgery simulates or
mimics a surgical procedure, the person does not actually
undergo the full surgical procedure.’’) This placebo-
controlled feasibility trial highlighted as an implication for
Table 1. Characteristics of placebo-controlled trials of invasive
procedures, n 5 96















Orthopedics & trauma 15 (16)
Oral and maxillofacial 10 (10)
Cardiothoracic 7 (7)
Ear, nose, and throat 6 (6)








Not reported 25 (26)






Minimal access 21 (22)
Percutaneous 20 (21)
Open surgery 11 (11)
a Gynecology and obstetrics, n 5 4; urology, n 5 2; podiatry,
n 5 2.
b Not reported for 1 trial (recruitment not completed).
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controlled trials should explicitly state that while benefit
might be seen within a placebo group, the underlying mech-
anism of the placebo has no known direct effect’’ [39].3.4. Offering the treatment intervention to patients
randomized to the placebo group
Patients allocated to the placebo group were offered the
treatment intervention in 43 (45%) trials. Seven (7%) werecrossover trials where all patients received both treatment
and placebo interventions. This included one trial with a
four-group design in which the order that interventions
were delivered was randomized [40]. At least one rationale
for offering treatment to the placebo group was given by 16
(37%). Seven stated that the treatment intervention was
offered if patients had continuing symptoms. In five, ethical
reasons were specified, for example, ‘‘for ethical reasons,
patients in the sham group had callosities debrided before
leaving the clinic’’ [41]. Some trials also reported that of-
fering the treatment to all patients was a strategy to opti-
mize recruitment and retention (n 5 5), with one stating
that ‘‘asking patients to remain untreated risked their
noncompliance with follow-up evaluation’’ [42]. Methodo-
logical advantages of this approach were cited by three tri-
als; patients could act as their own controls in a trial with a
crossover design [43]; delivery of treatment after placebo
‘‘provided the opportunity to investigate whether [the treat-
ment intervention] would be of secondary benefit after suc-
cessful or failed primary (sham) treatment’’ [40]; and
offering patients the treatment intervention may reduce
the likelihood of patients seeking treatments outside of
the study protocol [42].3.5. Delivery of co-interventions in the placebo group
Details about any co-intervention delivered preproce-
dure, periprocedure, and postprocedure were reported in
45 (47%), 31 (32%), and 64 (67%) of trials, respectively.
Explicit matching of co-interventions between treatment
and placebo groups was reported in 42/45 (preprocedure),
27/31 (peri-procedure) and 61/64 (postprocedure). Anes-
thesia was matched between groups in 64 trials (67%).
Types of anesthesia used in these trials included sedation
(n 5 23, 36%), local (including regional blocks) (n 5 20,
31%), general (n 5 13, 20%), and combinations (n 5 7,
11%). In one study, it was unclear which type of anesthesia
was used.3.6. Intervention standardization and fidelity
Attempts to standardize trial interventions were reported
in 6 trials (6%). Four trials reported that interventions were
delivered in accordance with a protocol [23,44e46]: One
reported the use of a standardized protocol for delivering
treatment interventions only [46]; one specified both treat-
ment and placebo interventions were delivered using the
same standardized protocol [44]; one specified that all op-
erators adhered to a standardized protocol but gave no
further detail [23]; and one specified that surgeons were al-
lowed to apply their own techniques within the limits of the
protocol [45]. Another trial reported that consensus on a
standard intervention approach was reached by all partici-
pating investigators and a treatment consultant at a prestudy
meeting [47], and one reported that uniformity of
114 S. Cousins et al. / Journal of Clinical Epidemiology 119 (2020) 109e116intervention delivery was ensured by the use of just one
clinician to deliver all interventions [48].
Four trials (4%) reported strategies to monitor the deliv-
ery of interventions (fidelity). In three, the interventions
were videotaped [33,45,49] and the other stated that
‘‘adherence to technique was monitored by the Study
Chairman’’ [47], although no further details were given.4. Discussion
Placebo-controlled trials of invasive procedures are
controversial and can be challenging to conduct. This sys-
tematic review identified 96 such trials. Most evaluated
minimally invasive endoscopic procedures, with only 11
trials of traditional ‘‘open’’ surgeries involving an incision.
Owing to the potential for patient risk in these trials, careful
consideration is needed to justify their use [14,16,17].
Despite this, a third of trials did not provide a rationale
for the placebo-controlled design and strategies to mini-
mize potential risk to patients were poorly reported. Con-
tradictory information about the use of an invasive
placebo intervention was also given to patients across trials;
some trials informed patients the placebo intervention
would not benefit their condition [31e33], whereas another
specified that it would [34]. A large proportion of trials also
offered the treatment intervention to patients randomized to
the placebo group. Although ethical reasons were some-
times cited for this, further consideration of the potential
added risk of offering patients an additional treatment with
unproven benefit is required. There is therefore a need for
better guidance for the design, conduct, and reporting of
placebo RCTs in invasive procedures, including surgery.
In agreement with previous reviews [9,10], most RCTs
with an invasive placebo intervention evaluated minimally
invasive treatments. Although the RCTs evaluated treat-
ments from across specialties, most were conducted in
gastro-intestinal surgery, where minimally invasive tech-
niques are commonly used (e.g., endoscopic procedures).
In addition, in keeping with previous reviews of surgical
RCTs [50e52], the standard of reporting in the RCTs
across the examined methodological areas of interest was
inconsistent. One area that was poorly reported was the
rationale for using an invasive placebo comparator within
the RCT. Guidance issued by the American Medical Asso-
ciation [14], specifies the ethical use of invasive placebo in-
terventions only in cases where no other trial design will
yield the requisite data. However, one-third of trials did
not report any rationale for the use of an invasive placebo
comparator, in place of standard or no treatment compara-
tors. This guidance and others [15e17] also highlight the
need for rigorous informed consent processes in placebo
surgical trials, including providing patients with informa-
tion that describes the differences between treatment and
placebo interventions and the risk posed by each. Despite
this, the reporting of information provision to patientsregarding the use of an invasive placebo intervention was
poor. In addition, although it is a key issue to consider in
RCTs with an invasive placebo comparator, strategies to
minimize potential risk to patients, such as additional over-
sight mechanisms, were poorly reported. However, it is
possible that clinical methods to minimize risk (e.g., highly
selecting patients or consideration of different modes of
anesthesia) were used in the trials.
Findings highlight the need for reporting guidelines re-
flecting methodological best practice for the design and de-
livery of placebo-controlled studies of invasive procedures.
As with existing reporting guidelines for RCTs [53], this
would include the minimum detail that researchers should
state in trial protocols and in the reporting of results to
ensure transparency and consistency across studies. Key
methodological areas that currently have considerable gaps
in the quantity and quality of reported information include
justification for use of an invasive placebo, minimization of
patient risk, patient information provision regarding pla-
cebo use, rationales for offering patients to the placebo
group the treatment intervention, and standardization of in-
terventions across patients/trial sites.
The current review comprehensively identified all
publications of placebo-controlled trials of invasive pro-
cedures using systematic methods, including handsearch-
ing references and expert knowledge. However,
additional details about the RCTs may possibly have
been gained from contacting trial teams directly, and this
may have provided further insight into the design and de-
livery of these trials. Although this was not practically
possible for the current review, it is important that future
work to improve the design and reporting of these RCTs
involves key stakeholders, including trialists, clinicians,
and journal representatives. We also acknowledge that
assessments of risk of bias [54] may have provided valu-
able information about the quality of the included RCTs
[55]. However, given the focus of this review on specific
key methodological issues not reported in previous re-
views, it was not included. Furthermore, it should be
highlighted that the inconsistent reporting of these trials
may in part reflect journal restrictions on manuscript
length, a limitation common to all reviews of published
articles.
This review demonstrates that placebo-controlled trials
of invasive procedures are being undertaken in a range of
surgical specialties (but especially in gastro-intestinal sur-
gery); however, they are poorly reported, an issue common
to all RCTs in surgery [50e52]. In addition to the develop-
ment of reporting guidelines, more work is needed to
develop guidance to optimize the design and conduct of
RCTs in this field, and it is important that this be carried
out in consultation with patients and key stakeholders to
ensure acceptability. Placebo-controlled trials have the po-
tential to answer important clinical questions [20,31]; how-
ever, there is a need to ensure standardization and
implementation of appropriate methods across RCTs.
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